BRPI0407818A - sistema de distribuição subcutánea, processo para a preparação do mesmo e uso do mesmo para o tratamento das doenças da deficiência colinérgica - Google Patents

sistema de distribuição subcutánea, processo para a preparação do mesmo e uso do mesmo para o tratamento das doenças da deficiência colinérgica

Info

Publication number
BRPI0407818A
BRPI0407818A BRPI0407818-7A BRPI0407818A BRPI0407818A BR PI0407818 A BRPI0407818 A BR PI0407818A BR PI0407818 A BRPI0407818 A BR PI0407818A BR PI0407818 A BRPI0407818 A BR PI0407818A
Authority
BR
Brazil
Prior art keywords
preparation
group
treatment
distribution system
deficiency diseases
Prior art date
Application number
BRPI0407818-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Rolland-Yves Mauvernay
Herve Porchet
Pietro Scalfaro
Frederic Heimgatner
Bertrand Ducrey
Francois Pfeffferle
Sergio Capancioni
Mark Mc Cormick
Original Assignee
Debio Rech Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debio Rech Pharma Sa filed Critical Debio Rech Pharma Sa
Publication of BRPI0407818A publication Critical patent/BRPI0407818A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BRPI0407818-7A 2003-03-14 2004-03-15 sistema de distribuição subcutánea, processo para a preparação do mesmo e uso do mesmo para o tratamento das doenças da deficiência colinérgica BRPI0407818A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB0300942 2003-03-14
IB0304945 2003-11-05
PCT/IB2004/000734 WO2004080436A1 (en) 2003-03-14 2004-03-15 Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders

Publications (1)

Publication Number Publication Date
BRPI0407818A true BRPI0407818A (pt) 2006-02-14

Family

ID=32992641

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407818-7A BRPI0407818A (pt) 2003-03-14 2004-03-15 sistema de distribuição subcutánea, processo para a preparação do mesmo e uso do mesmo para o tratamento das doenças da deficiência colinérgica

Country Status (23)

Country Link
US (1) US20070059369A1 (enExample)
EP (2) EP1603532B1 (enExample)
JP (1) JP2006520378A (enExample)
KR (1) KR20060023111A (enExample)
AT (1) ATE404170T1 (enExample)
AU (1) AU2004218896B2 (enExample)
BR (1) BRPI0407818A (enExample)
CA (1) CA2518883A1 (enExample)
CY (1) CY1108482T1 (enExample)
DE (1) DE602004015744D1 (enExample)
DK (1) DK1603532T3 (enExample)
EA (1) EA011169B1 (enExample)
ES (1) ES2312981T3 (enExample)
IL (1) IL170759A (enExample)
IS (1) IS8067A (enExample)
MX (1) MXPA05009626A (enExample)
NO (1) NO20054258L (enExample)
NZ (1) NZ542459A (enExample)
PL (1) PL1603532T3 (enExample)
PT (1) PT1603532E (enExample)
SI (1) SI1603532T1 (enExample)
UA (1) UA82226C2 (enExample)
WO (1) WO2004080436A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2432556T3 (es) 2004-08-04 2013-12-04 Evonik Corporation Métodos para fabricar dispositivos de suministro y sus dispositivos
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US8956636B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
WO2011132157A1 (en) 2010-04-22 2011-10-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Oral sustained release formulation of huperzine a
WO2013173096A2 (en) * 2012-05-18 2013-11-21 Insero Health Inc. Conjugates of huperzine and analogs thereof
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
JP7111375B2 (ja) * 2017-10-19 2022-08-02 株式会社佐藤園 学習記憶能力増強組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106979A (en) * 1989-02-21 1992-04-21 University Of Pittsburgh Method for the synthesis of huperzine A and analogs thereof and compounds useful therein
CN1125725A (zh) * 1994-12-28 1996-07-03 中国科学院上海药物研究所 一类海克林碱衍生物及它的用途
FR2756493B1 (fr) * 1996-12-02 2001-04-13 Delab Dispositif d'administration locale de formulations solides ou semi-solides
US6352715B1 (en) 1998-02-19 2002-03-05 Sagittarius Life Science Corp Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
CN1279065A (zh) 1999-07-06 2001-01-10 青岛科达生物工程有限公司 一种治疗记忆障碍和老年痴呆的药物组合物
CN1194688C (zh) * 2001-07-03 2005-03-30 山东绿叶制药股份有限公司 石杉碱甲及其衍生物或其盐的注射用缓释微球及其制备方法
CN1383824A (zh) 2002-05-21 2002-12-11 浙江省医学科学院 石杉碱鼻腔给药制剂

Also Published As

Publication number Publication date
IL170759A (en) 2010-06-16
EA011169B1 (ru) 2009-02-27
EP1977735A1 (en) 2008-10-08
EP1603532A1 (en) 2005-12-14
DK1603532T3 (da) 2008-12-08
AU2004218896A1 (en) 2004-09-23
HK1089085A1 (zh) 2006-11-24
ES2312981T3 (es) 2009-03-01
NZ542459A (en) 2008-12-24
AU2004218896B2 (en) 2010-04-01
SI1603532T1 (sl) 2009-02-28
DE602004015744D1 (de) 2008-09-25
IS8067A (is) 2005-10-11
CA2518883A1 (en) 2004-09-23
US20070059369A1 (en) 2007-03-15
EA200501433A1 (ru) 2006-02-24
PL1603532T3 (pl) 2009-02-27
CY1108482T1 (el) 2014-04-09
NO20054258D0 (no) 2005-09-15
WO2004080436A1 (en) 2004-09-23
MXPA05009626A (es) 2005-10-18
NO20054258L (no) 2005-11-24
EP1603532B1 (en) 2008-08-13
PT1603532E (pt) 2008-11-20
ATE404170T1 (de) 2008-08-15
JP2006520378A (ja) 2006-09-07
KR20060023111A (ko) 2006-03-13
UA82226C2 (uk) 2008-03-25

Similar Documents

Publication Publication Date Title
CY1108482T1 (el) Συστημα υποδοριας διανομης, μεθοδος παρασκευης του και χρηση του για την αγωγη διαταραχων xολινεργικης ανεπαρκειας
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BR0215429A (pt) Composto de fórmula i e seus usos, métodos de inibição da atividade e método de inibição da ativação de um receptor de monoamina, métodos de tratamento, método de identificação de polimorfismo genético e método de identificação de paciente
AU7522601A (en) Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
BR0115531A (pt) Tratamento de mucosites
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
CO5180642A1 (es) Compuestos sustituidos de piperidina, procesos para su prepa racion, composiciones farmaceuticas que los contienen y su utilizacion
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BR0210631A (pt) Composição farmacêutica de liberação prolongada
BRPI0400214A (pt) Composições e aplicações farmacêuticas para a obtenção confiável de nìveis aceitáveis de testosterona no soro
BR0315580A (pt) Derivados de metileno uréia
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
BR0012610A (pt) Novo derivado de difenilpiperidina
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
BR0111897A (pt) Composto, método para tratar um indivìduo afligido por alguns distúrbios dos sistemas nervosos periférico e central, composição farmacêutica, e, uso de um composto
DK1534352T3 (da) Implantat til transport og afgivelse af farmakologisk aktive midler såvel som en fremgangsmåde til fremstilling af samme
BR0210401A (pt) Composto, composição farmacêutica, uso de um composto e método para o tratamento de um distúrbio ou de uma doença de um corpo de animal vivo, incluindo um humano
DK1332764T3 (da) Mucoadhæsivt, termoresponsivt lægemiddel-bærer-præparat

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.